Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Beyond The T/C Ratio: Old And New Anticancer Activity Scores In Vivo.

Ubezio P.

Cancer Manag Res. 2019 Sep 19;11:8529-8538. doi: 10.2147/CMAR.S215729. eCollection 2019.

2.

Combination of PPARg agonist pioglitazone and trabectedin induce adipocyte differentiation to overcome trabectedin resistance in myxoid liposarcomas.

Frapolli R, Bello E, Ponzo M, Craparotta I, Mannarino L, Ballabio S, Marchini S, Carrassa L, Ubezio P, Porcu L, Brich S, Sanfilippo R, Casali PG, Gronchi A, Pilotti S, D'Incalci M.

Clin Cancer Res. 2019 Sep 3. pii: clincanres.0976.2019. doi: 10.1158/1078-0432.CCR-19-0976. [Epub ahead of print]

PMID:
31481505
3.

HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases.

Paroni G, Bolis M, Zanetti A, Ubezio P, Helin K, Staller P, Gerlach LO, Fratelli M, Neve RM, Terao M, Garattini E.

Oncogene. 2019 Apr;38(15):2675-2689. doi: 10.1038/s41388-018-0620-6. Epub 2018 Dec 11.

PMID:
30538297
4.

Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging.

Falcetta F, Morosi L, Ubezio P, Giordano S, Decio A, Giavazzi R, Frapolli R, Prasad M, Franceschi P, D'Incalci M, Davoli E.

Anal Chim Acta. 2018 Dec 26;1042:1-10. doi: 10.1016/j.aca.2018.06.067. Epub 2018 Jun 28.

PMID:
30428975
5.

ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells.

Portale F, Cricrì G, Bresolin S, Lupi M, Gaspari S, Silvestri D, Russo B, Marino N, Ubezio P, Pagni F, Vergani P, Kronnie GT, Valsecchi MG, Locatelli F, Rizzari C, Biondi A, Dander E, D'Amico G.

Haematologica. 2019 Mar;104(3):533-545. doi: 10.3324/haematol.2018.188664. Epub 2018 Sep 27.

6.

Self-Assembling PCL-Based Nanoparticles as PTX Solubility Enhancer Excipients.

Capasso Palmiero U, Morosi L, Lupi M, Ponzo M, Frapolli R, Zucchetti M, Ubezio P, Morbidelli M, D'Incalci M, Bello E, Moscatelli D.

Macromol Biosci. 2018 Oct;18(10):e1800164. doi: 10.1002/mabi.201800164. Epub 2018 Jul 25.

PMID:
30047229
7.

Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.

Bizzaro F, Falcetta F, D'Agostini E, Decio A, Minoli L, Erba E, Alessandro Peccatori F, Scanziani E, Colombo N, Zucchetti M, Bani MR, Ubezio P, Giavazzi R.

Int J Cancer. 2018 Nov 1;143(9):2187-2199. doi: 10.1002/ijc.31596. Epub 2018 Aug 7.

PMID:
29752717
8.

Application of 3D Mass Spectrometry Imaging to TKIs.

Morosi L, Giordano S, Falcetta F, Frapolli R, Licandro SA, Matteo C, Zucchetti M, Ubezio P, Erba E, Visentin S, D'Incalci M, Davoli E.

Clin Pharmacol Ther. 2017 Nov;102(5):748-751. doi: 10.1002/cpt.786.

PMID:
29023728
9.

Modeling Cytostatic and Cytotoxic Responses to New Treatment Regimens for Ovarian Cancer.

Falcetta F, Bizzaro F, D'Agostini E, Bani MR, Giavazzi R, Ubezio P.

Cancer Res. 2017 Dec 1;77(23):6759-6769. doi: 10.1158/0008-5472.CAN-17-1099. Epub 2017 Sep 26.

10.

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.

Vázquez R, Licandro SA, Astorgues-Xerri L, Lettera E, Panini N, Romano M, Erba E, Ubezio P, Bello E, Libener R, Orecchia S, Grosso F, Riveiro ME, Cvitkovic E, Bekradda M, D'Incalci M, Frapolli R.

Int J Cancer. 2017 Jan 1;140(1):197-207. doi: 10.1002/ijc.30412. Epub 2016 Sep 19.

11.

Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer.

Ubezio P, Falcetta F, Carrassa L, Lupi M.

Oncotarget. 2016 Mar 29;7(13):15492-506. doi: 10.18632/oncotarget.7491.

12.

Small interfering RNA delivery through positively charged polymer nanoparticles.

Dragoni L, Ferrari R, Lupi M, Cesana A, Falcetta F, Ubezio P, D'Incalci M, Morbidelli M, Moscatelli D.

Nanotechnology. 2016 Mar 29;27(12):125102. doi: 10.1088/0957-4484/27/12/125102. Epub 2016 Feb 18.

PMID:
26891480
13.

Fate of PLA and PCL-Based Polymeric Nanocarriers in Cellular and Animal Models of Triple-Negative Breast Cancer.

Sitia L, Ferrari R, Violatto MB, Talamini L, Dragoni L, Colombo C, Colombo L, Lupi M, Ubezio P, D'Incalci M, Morbidelli M, Salmona M, Moscatelli D, Bigini P.

Biomacromolecules. 2016 Mar 14;17(3):744-55. doi: 10.1021/acs.biomac.5b01422. Epub 2016 Feb 2.

PMID:
26791775
14.

PEGylated Nanoparticles Obtained through Emulsion Polymerization as Paclitaxel Carriers.

Colombo C, Morosi L, Bello E, Ferrari R, Licandro SA, Lupi M, Ubezio P, Morbidelli M, Zucchetti M, D'Incalci M, Moscatelli D, Frapolli R.

Mol Pharm. 2016 Jan 4;13(1):40-6. doi: 10.1021/acs.molpharmaceut.5b00383. Epub 2015 Dec 11.

PMID:
26623665
15.

Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.

Decio A, Cesca M, Bizzaro F, Porcu L, Bettolini R, Ubezio P, Taraboletti G, Belotti D, Giavazzi R.

Clin Exp Metastasis. 2015 Oct;32(7):647-58. doi: 10.1007/s10585-015-9734-1. Epub 2015 Jul 17.

PMID:
26185056
16.

Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expression.

Centritto F, Paroni G, Bolis M, Garattini SK, Kurosaki M, Barzago MM, Zanetti A, Fisher JN, Scott MF, Pattini L, Lupi M, Ubezio P, Piccotti F, Zambelli A, Rizzo P, Gianni' M, Fratelli M, Terao M, Garattini E.

EMBO Mol Med. 2015 Jul;7(7):950-72. doi: 10.15252/emmm.201404670.

17.

A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma.

Lupi M, Colombo C, Frapolli R, Ferrari R, Sitia L, Dragoni L, Bello E, Licandro SA, Falcetta F, Ubezio P, Bigini P, Salmona M, D'Incalci M, Morbidelli M, Moscatelli D.

Nanotechnology. 2014 Aug 22;25(33):335706. doi: 10.1088/0957-4484/25/33/335706. Epub 2014 Jul 30.

PMID:
25074670
18.

Integrated multiplatform method for in vitro quantitative assessment of cellular uptake for fluorescent polymer nanoparticles.

Ferrari R, Lupi M, Falcetta F, Bigini P, Paolella K, Fiordaliso F, Bisighini C, Salmona M, D'Incalci M, Morbidelli M, Moscatelli D, Ubezio P.

Nanotechnology. 2014 Jan 31;25(4):045102.

PMID:
24398665
19.

Modeling of non-small cell lung cancer volume changes during CT-based image guided radiotherapy: patterns observed and clinical implications.

Gay HA, Taylor QQ, Kiriyama F, Dieck GT, Jenkins T, Walker P, Allison RR, Ubezio P.

Comput Math Methods Med. 2013;2013:637181. doi: 10.1155/2013/637181. Epub 2013 Oct 24.

20.

Dynamic rendering of the heterogeneous cell response to anticancer treatments.

Falcetta F, Lupi M, Colombo V, Ubezio P.

PLoS Comput Biol. 2013;9(10):e1003293. doi: 10.1371/journal.pcbi.1003293. Epub 2013 Oct 17.

21.

Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.

Zucchetti M, Bonezzi K, Frapolli R, Sala F, Borsotti P, Zangarini M, Cvitkovic E, Noel K, Ubezio P, Giavazzi R, D'Incalci M, Taraboletti G.

Cancer Chemother Pharmacol. 2013 Oct;72(4):879-87. doi: 10.1007/s00280-013-2270-2. Epub 2013 Aug 24.

PMID:
23978989
22.

A methyl methacrylate-HEMA-CL(n) copolymerization investigation: from kinetics to bioapplications.

Ferrari R, Rooney TR, Lupi M, Ubezio P, Hutchinson RA, Moscatelli D.

Macromol Biosci. 2013 Oct;13(10):1347-57. doi: 10.1002/mabi.201300152. Epub 2013 Jul 19.

PMID:
23873662
23.

Synthesis of surfactant free PCL-PEG brushed nanoparticles with tunable degradation kinetics.

Ferrari R, Colombo C, Casali C, Lupi M, Ubezio P, Falcetta F, D'Incalci M, Morbidelli M, Moscatelli D.

Int J Pharm. 2013 Sep 10;453(2):551-9. doi: 10.1016/j.ijpharm.2013.06.020. Epub 2013 Jun 21.

PMID:
23796832
24.

Biocompatible fluorescent nanoparticles for in vivo stem cell tracking.

Cova L, Bigini P, Diana V, Sitia L, Ferrari R, Pesce RM, Khalaf R, Bossolasco P, Ubezio P, Lupi M, Tortarolo M, Colombo L, Giardino D, Silani V, Morbidelli M, Salmona M, Moscatelli D.

Nanotechnology. 2013 Jun 21;24(24):245603. doi: 10.1088/0957-4484/24/24/245603. Epub 2013 May 20.

PMID:
23690139
25.

Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies.

Bonezzi K, Belotti D, North BJ, Ghilardi C, Borsotti P, Resovi A, Ubezio P, Riva A, Giavazzi R, Verdin E, Taraboletti G.

Neoplasia. 2012 Sep;14(9):846-54.

26.

A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK, D'Incalci M, De Placido S, Pepe S.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1113-9. doi: 10.1016/j.ijrobp.2011.09.030. Epub 2011 Dec 13.

PMID:
22172905
27.

Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.

Paroni G, Fratelli M, Gardini G, Bassano C, Flora M, Zanetti A, Guarnaccia V, Ubezio P, Centritto F, Terao M, Garattini E.

Oncogene. 2012 Jul 19;31(29):3431-43. doi: 10.1038/onc.2011.506. Epub 2011 Nov 7.

PMID:
22056878
28.

Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical models.

Di Francesco AM, Ubezio P, Torella AR, Meco D, Pierri F, Barone G, Cusano G, Pisano C, D'Incalci M, Riccardi R.

Invest New Drugs. 2012 Aug;30(4):1319-30. doi: 10.1007/s10637-011-9689-2. Epub 2011 Jun 3.

PMID:
21633925
29.

Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates.

Mazzoletti M, Bortolin F, Brunelli L, Pastorelli R, Di Giandomenico S, Erba E, Ubezio P, Broggini M.

Cancer Res. 2011 Jul 1;71(13):4573-84. doi: 10.1158/0008-5472.CAN-10-4322. Epub 2011 May 20.

30.

Interoperability of time series cytometric data: a cross platform approach for modeling tumor heterogeneity.

Khan IA, Lupi M, Campbell L, Chappell SC, Brown MR, Wiltshire M, Smith PJ, Ubezio P, Errington RJ.

Cytometry A. 2011 Mar;79(3):214-26. doi: 10.1002/cyto.a.21023. Epub 2011 Feb 18.

31.

Miniaturizing bromodeoxyuridine incorporation enables the usage of flow cytometry for cell cycle analysis of adherent tissue culture cells for high throughput screening.

Cappella P, Giorgini ML, Ernestina Re C, Ubezio P, Ciomei M, Moll J.

Cytometry A. 2010 Oct;77(10):953-61. doi: 10.1002/cyto.a.20962. Epub 2010 Sep 8.

32.

Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells.

Colombo V, Lupi M, Falcetta F, Forestieri D, D'Incalci M, Ubezio P.

Cancer Chemother Pharmacol. 2011 Feb;67(2):369-79. doi: 10.1007/s00280-010-1335-8. Epub 2010 Apr 30.

PMID:
20431887
33.

Quantitative assessment of the complex dynamics of G1, S, and G2-M checkpoint activities.

Ubezio P, Lupi M, Branduardi D, Cappella P, Cavallini E, Colombo V, Matera G, Natoli C, Tomasoni D, D'Incalci M.

Cancer Res. 2009 Jun 15;69(12):5234-40. doi: 10.1158/0008-5472.CAN-08-3911. Epub 2009 Jun 9.

34.

Cell killing and resistance in pre-operative breast cancer chemotherapy.

Ubezio P, Cameron D.

BMC Cancer. 2008 Jul 21;8:201. doi: 10.1186/1471-2407-8-201.

35.

In vivo measurement of vascular modulation in experimental tumors using a fluorescent contrast agent.

Valentini G, D'Andrea C, Ferrari R, Pifferi A, Cubeddu R, Martinelli M, Natoli C, Ubezio P, Giavazzi R.

Photochem Photobiol. 2008 Sep-Oct;84(5):1249-56. doi: 10.1111/j.1751-1097.2008.00352.x. Epub 2008 Apr 12.

PMID:
18422875
36.

Antiproliferative activity of cisplatin detected by CFSE in p53-proficient and p53-deficient cells.

Ubezio P, Lupi M, Matera G.

Immunol Invest. 2007;36(5-6):847-59.

PMID:
18161532
38.

The contribution of p53 in the dynamics of cell cycle response to DNA damage interpreted by a mathematical model.

Lupi M, Matera G, Natoli C, Colombo V, Ubezio P.

Cell Cycle. 2007 Apr 15;6(8):943-50. Epub 2007 Apr 2.

PMID:
17387280
39.
40.

Modelling the balance between quiescence and cell death in normal and tumour cell populations.

Spinelli L, Torricelli A, Ubezio P, Basse B.

Math Biosci. 2006 Aug;202(2):349-70. Epub 2006 Mar 28.

PMID:
16697424
41.

Neurodegeneration induced by complex I inhibition in a cellular model of familial amyotrophic lateral sclerosis.

Rizzardini M, Lupi M, Mangolini A, Babetto E, Ubezio P, Cantoni L.

Brain Res Bull. 2006 Apr 28;69(4):465-74. Epub 2006 Mar 10.

PMID:
16624679
42.

The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.

Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, Scanziani E, Eccles SA, Bani MR, Giavazzi R.

Clin Cancer Res. 2006 Mar 15;12(6):1839-49.

43.

Gerstmann-Sträussler-Scheinker disease amyloid protein polymerizes according to the "dock-and-lock" model.

Gobbi M, Colombo L, Morbin M, Mazzoleni G, Accardo E, Vanoni M, Del Favero E, Cantù L, Kirschner DA, Manzoni C, Beeg M, Ceci P, Ubezio P, Forloni G, Tagliavini F, Salmona M.

J Biol Chem. 2006 Jan 13;281(2):843-9. Epub 2005 Nov 10.

44.

Interpreting cell cycle effects of drugs: the case of melphalan.

Lupi M, Cappella P, Matera G, Natoli C, Ubezio P.

Cancer Chemother Pharmacol. 2006 Apr;57(4):443-57. Epub 2005 Sep 30.

PMID:
16195878
45.

Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.

Riccardi A, Meco D, Ubezio P, Mazzarella G, Marabese M, Faircloth GT, Jimeno J, D'Incalci M, Riccardi R.

Anticancer Drugs. 2005 Sep;16(8):811-5.

PMID:
16096428
46.

Low levels of ALS-linked Cu/Zn superoxide dismutase increase the production of reactive oxygen species and cause mitochondrial damage and death in motor neuron-like cells.

Rizzardini M, Mangolini A, Lupi M, Ubezio P, Bendotti C, Cantoni L.

J Neurol Sci. 2005 May 15;232(1-2):95-103.

PMID:
15850589
47.

Heterogeneous cell response to topotecan in a CFSE-based proliferation test.

Matera G, Lupi M, Ubezio P.

Cytometry A. 2004 Dec;62(2):118-28.

48.

Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approach.

Lupi M, Matera G, Branduardi D, D'Incalci M, Ubezio P.

Cancer Res. 2004 Apr 15;64(8):2825-32.

49.

Calpain as a multi-site regulator of cell cycle.

Jánossy J, Ubezio P, Apáti A, Magócsi M, Tompa P, Friedrich P.

Biochem Pharmacol. 2004 Apr 15;67(8):1513-21.

PMID:
15041468
50.

The combination of yondelis and cisplatin is synergistic against human tumor xenografts.

D'Incalci M, Colombo T, Ubezio P, Nicoletti I, Giavazzi R, Erba E, Ferrarese L, Meco D, Riccardi R, Sessa C, Cavallini E, Jimeno J, Faircloth GT.

Eur J Cancer. 2003 Sep;39(13):1920-6.

PMID:
12932672

Supplemental Content

Loading ...
Support Center